Back to Search
Start Over
Comparison of radioligand assay and immunostaining for epidermal growth factor receptor in human breast cancer
- Source :
- British Journal of Surgery. 81:853-855
- Publication Year :
- 1994
- Publisher :
- Oxford University Press (OUP), 1994.
-
Abstract
- Epidermal growth factor (EGF) receptor status is a useful prognostic indicator in women with breast cancer. Lack of standardization and correlation of methodology for the detection of EGF receptor has hampered its further evaluation. EGF receptor status was ascertained by immunohistochemistry and radioligand assay in 120 breast cancers. Of 52 tumours negative for EGF receptor on radioligand assay, 47 were negative on immunohistochemistry and, of 68 tumours positive for the receptor on assay, 52 were positive on immunohistochemistry. If the more widely evaluated radioligand assay is assumed to be the ‘gold standard’, immunohistochemistry has a sensitivity of 81 per cent and a specificity of 91 per cent.
- Subjects :
- Receptor Status
Pathology
medicine.medical_specialty
Mammary gland
Breast Neoplasms
Sensitivity and Specificity
Immunoenzyme Techniques
Radioligand Assay
Breast cancer
Predictive Value of Tests
Epidermal growth factor
Biomarkers, Tumor
medicine
Humans
Epidermal growth factor receptor
biology
business.industry
Cancer
medicine.disease
ErbB Receptors
medicine.anatomical_structure
Cancer research
biology.protein
Immunohistochemistry
Female
Surgery
business
Subjects
Details
- ISSN :
- 13652168 and 00071323
- Volume :
- 81
- Database :
- OpenAIRE
- Journal :
- British Journal of Surgery
- Accession number :
- edsair.doi.dedup.....352a9b93b802dd8e7febd07b85206b51
- Full Text :
- https://doi.org/10.1002/bjs.1800810620